MMI raises $125 million in Series D led by BioStar, joined by S3 Ventures

Medical Microinstruments (MMI), a surgical robotics developer, raised $125 million in a Series D financing. BioStar Capital led the round; S3 Ventures joined as a new investor alongside Angelini Ventures and an undisclosed strategic investor. Proceeds target commercial expansion in the U.S. and other key markets for MMI’s Symani microsurgery system. MMI reported about 50 installed systems and 3,500 procedures completed worldwide using Symani. Funding also supports clinical trials and outcomes data generation, including the REMIND study, to broaden Symani’s use cases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. S3 Ventures LLC published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein. (C)